By SPC News Staff
The FDA granted a new indication for pembrolizumab (Keytruda), Merck’s anti?PD-1 therapy, for the adjuvant treatment of adults and children ages 12 years and older with stage IIB or IIC melanoma following complete resection.
Additionally, the FDA expanded the indication for pembrolizumab as an adjuvant treatment for stage III melanoma following complete resection to include pediatric patients (12 years and older).